NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis $10.59 +0.20 (+1.92%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$10.56 -0.04 (-0.33%) As of 05/23/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BCRX alerts:Sign Up Key Stats Today's Range$10.16▼$10.5950-Day Range$6.41▼$11.0352-Week Range$5.92▼$11.11Volume3.61 million shsAverage Volume3.03 million shsMarket Capitalization$2.22 billionP/E RatioN/ADividend YieldN/APrice Target$16.56Consensus RatingModerate Buy Company OverviewBioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Read More… BioCryst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreBCRX MarketRank™: BioCryst Pharmaceuticals scored higher than 93% of companies evaluated by MarketBeat, and ranked 76th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioCryst Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioCryst Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.36) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -17.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -17.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCryst Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.75% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently decreased by 10.47%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.85 Percentage of Shares Shorted8.75% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently decreased by 10.47%, indicating that investor sentiment is improving significantly. News and Social Media4.1 / 5News Sentiment1.45 News SentimentBioCryst Pharmaceuticals has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for BioCryst Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest27 people have searched for BCRX on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows11 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioCryst Pharmaceuticals' insider trading history. Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Stock News HeadlinesBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by StockNews.comMay 22 at 1:31 AM | americanbankingnews.comBioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)May 16, 2025 | globenewswire.comVolatility Is Rising—But These 2 AI Stocks Could Thrive2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines. But even in uncertain times, innovation doesn’t slow down. In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles. Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar.May 25, 2025 | Darwin (Ad)BioCryst Pharmaceuticals (NASDAQ:BCRX) Rating Lowered to Buy at StockNews.comMay 16, 2025 | americanbankingnews.comBioCryst's Orladeyo up for FDA review in pediatric HAE patientsMay 14, 2025 | msn.comBioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 YearsMay 14, 2025 | globenewswire.comAnalysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest ResultsMay 8, 2025 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2025 Earnings Call TranscriptMay 6, 2025 | insidermonkey.comSee More Headlines BCRX Stock Analysis - Frequently Asked Questions How have BCRX shares performed this year? BioCryst Pharmaceuticals' stock was trading at $7.52 on January 1st, 2025. Since then, BCRX shares have increased by 40.8% and is now trading at $10.59. View the best growth stocks for 2025 here. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings results on Monday, February, 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.06. BioCryst Pharmaceuticals's revenue was up 40.8% on a year-over-year basis. Read the conference call transcript. Who are BioCryst Pharmaceuticals' major shareholders? Top institutional shareholders of BioCryst Pharmaceuticals include Vanguard Group Inc. (10.35%), Alkeon Capital Management LLC (3.45%), Millennium Management LLC (1.82%) and GW&K Investment Management LLC (1.38%). Insiders that own company stock include Jon P Stonehouse, Yarlagadda S Babu, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders, Michael L Jones and Steve Aselage. View institutional ownership trends. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Pfizer (PFE) and PayPal (PYPL). Company Calendar Last Earnings2/24/2025Today5/25/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:BCRX CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees530Year Founded1986Price Target and Rating Average Stock Price Target$16.56 High Stock Price Target$30.00 Low Stock Price Target$11.00 Potential Upside/Downside+56.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,540,000.00 Net Margins-30.01% Pretax Margin-30.08% Return on EquityN/A Return on Assets-24.06% Debt Debt-to-Equity RatioN/A Current Ratio2.78 Quick Ratio2.73 Sales & Book Value Annual Sales$503.49 million Price / Sales4.40 Cash FlowN/A Price / Cash FlowN/A Book Value($2.22) per share Price / Book-4.77Miscellaneous Outstanding Shares209,250,000Free Float197,191,000Market Cap$2.22 billion OptionableOptionable Beta1.08 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:BCRX) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.